Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F3,F4	Mar 11, 2019	C	132,740	—	A	132,740	I	Through Deerfield Private Design Fund III, L.P.
Common Stock^F2,F3,F4	Mar 11, 2019	C	23,333	—	A	156,073	I	Through Deerfield Private Design Fund III, L.P.
Common Stock^F1,F3,F4	Mar 11, 2019	C	132,740	—	A	132,740	I	Through Deerfield Special Situations Fund, L.P.
Common Stock^F2,F3,F4	Mar 11, 2019	C	23,333	—	A	156,073	I	Through Deerfield Special Situations Fund, L.P.
Common Stock^F3,F4	Mar 11, 2019	P	10,000	$17.00	A	166,073	I	Through Deerfield Private Design Fund III, L.P.
Common Stock^F3,F4	Mar 11, 2019	P	10,000	$17.00	A	166,073	I	Through Deerfield Special Situations Fund, L.P.
Common Stock^F3,F4	Mar 11, 2019	P	10,000	$17.00	A	10,000	I	Through Deerfield Partners, L.P.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series B Preferred Stock^F1,F3,F4	—	Mar 11, 2019	C	1,619,433	D	—	—	Common Stock	132,740	I
Series C Preferred Stock^F2,F3,F4	—	Mar 11, 2019	C	284,659	D	—	—	Common Stock	23,333	I
Series B Preferred Stock^F1,F3,F4	—	Mar 11, 2019	C	1,619,433	D	—	—	Common Stock	132,740	I
Series C Preferred Stock^F2,F3,F4	—	Mar 11, 2019	C	284,659	D	—	—	Common Stock	23,333	I

Explanation of responses

F1Each share of Series B Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-12.2 reverse stock split effected by the Issuer on February 22, 2019).
F2Each share of Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-12.2 reverse stock split effected by the Issuer on February 22, 2019).
F3This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
F4In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.